


Lymphatic Filariasis (LF)

Why in News?

Union Health Minister launched National Mass Drug Administration (MDA) campaign for the elimination of Lymphatic Filariasis (LF) across 13 identified LF endemic states.

- Lymphatic filariasis (LF) It is a <u>Neglected Tropical Disease (NTD)</u>.
- Caused by Parasites classified as <u>nematodes</u> (roundworms) of the family Filariodidea.
- There are 3 types of these thread-like filarial worms
 - Wuchereria bancrofti, which is responsible for 90% of the cases
 - Brugia malayi, which causes most of the remainder of the cases
 - Brugia timori, which also causes the disease.
- Causes It damages the lymphatic system and the kidneys and alter the body's immune system.
- It is commonly known as *Elephantiasis or Hathi Paon*.
- Symptoms Asymptomatic, acute and chronic conditions which leads to,
 - Lymphoedema (tissue swelling) or elephantiasis (skin/tissue thickening) of limbs and hydrocele (scrotal swelling).



- **Transmission** It enters to human body through the bites of infected mosquitos to humans.
- Transmitted by Different types of mosquitoes,
 - Culex Widespread across urban and semi-urban areas.
 - **Anopheles** Found in rural areas.
 - **Aedes** Endemic in the islands of Pacific.
- **Risk factors** It is usually acquired in childhood.
- **Treatment** It is possible to stop the spread of the infection through preventive *chemotherapy*.
- **WHO recommendation** It recommended chemotherapy strategy for lymphatic filariasis elimination is *Mass Drug Administration (MDA)*.

Mass Drug Administration (MDA) involves administering an annual dose of medicines to the entire at-risk population.

• 5-pronged strategy to ensure that Lymphatic Filariasis (LF) is eliminated much ahead of the Sustainable Development Goal of 2030.

Mass Drug Administration (MDA) Campaign in India

- **Goal** To reduce the spread of LF by eliminating the microscopic filarial parasites present in the bloodstream of infected individuals.
- Coverage 111 endemic districts across <u>13 states</u>,
- Andhra Pradesh, Assam, Bihar, Chhattisgarh, Gujarat, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Uttar Pradesh, and West Bengal.
- **Medication regimen Double Drug (DA) -** Diethylcarbamazine Citrate (DEC) and Albendazole.
- Triple Drug (IDA) Ivermectin, Diethylcarbamazine Citrate (DEC), and Albendazole.

References

- 1. PIB Mass Drug Administration (MDA) Campaign for Lymphatic Filariasis (LF)
- 2. WHO| Lymphatic Filariasis (LF)

